DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

APPLICATION SERIAL NO.

My residence, post office address and citizenship are as stated below at 201 et seq. underneath my name.

I believe I am the original, first and sole inventor if only one name is listed at 201 below, or an original, first and joint inventor if plural names are listed at 201 et seq. below, of the subject matter which is claimed and for which a patent is sought on the invention entitled

METHODS FOR DETERMINING THERAPEUTIC INDEX FROM GENE EXPRESSION PROFILES

	Milio Indian de II		TOTAL OBIGE BAR	ideasion I Not had	
and for which a patent application: ☐ is attached hereto and includes amendment(☐ was filed in the United States on	er 28, 1998 as Appl	ication No	09/222,582 and was ame	:	
(if applicable)					
I hereby state that I have reviewed and unde amendment referred to above.	rstand the contents of the	e above iden	ified application,	including the claims, as	amended by an
I acknowledge the duty to disclose informatio §1:56.	n known to me to be mate	erial to paten	tability as defined	in Title 37, Code of Fed	leral Regulations
I hereby claim foreign priority benefits unde certificate listed below and have also identifie of the application on which priority is claimed.	d below any foreign appli	Code, §119(cation for pa	a)-(d) of any forei tent or inventor's	gn application(s) for pa certificate having a filin	tent or inventor' g date before the
EARLIEST FOREIGN APPLICAT	TION(S), IF ANY, FILE	D PRIOR TO	THE FILING DA	ATE OF THE APPLIC	ATION
EARLIEST FOREIGN APPLICATION NUMBER	COUNTRY		DATE OF FILIN (day, month, yea	IG PRIO	RITY
				YES 🗆	NO 🗆
				YES □	NO 🗆
Thereby claim the benefit under Title 35, Uni	ted States Code, §119(e)	of any Unite	d States provisiona		
APPLICATION NUMBER		FILING DATE			
APPLICATION NUMI					
The state of the s					
	<u>"</u>	<u> </u>			
I hereby claim the benefit under Title 35, Un matter of each of the claims of this application of Title 35, United States Code §112, I acknow of Federal Regulations, §1.56 which became a date of this application:	is not disclosed in the pri- ledge the duty to disclose	or United Sta information	tes application in the which is material to	he manner provided by to patentability as defined	the first paragrap

POWER OF ATTORNEY: As a named inventor, I hereby appoint S. Leslie Misrock (Reg. No. 18872), Harry C. Jones, III (Reg. No. 20280), Berj A. Terzian (Reg. No. 20060), Gerald J. Flintoft (Reg. No. 20823), David Weild, III (Reg. No. 21094), Jonathan A. Marshall (Reg. No. 24614), Barry D. Rein (Reg. No. 22411), Stanton T. Lawrence, III (Reg. No. 25736), Isaac Jarkovsky (Reg. No. 22713), Joseph V. Colaianni (Reg. No. 20019), Charles E. McKenney (Reg. No. 22795), Philip T. Shannon (Reg. No. 24278), Francis E. Morris (Reg. No. 24615), Charles E. Miller (Reg. No. 24576), Gidon D. Stern (Reg. No. 27469), John J. Lauter, Jr. (Reg. No. 27814), Brian M. Poissant (Reg. No. 28462), Brian D. Coggio (Reg. No. 27624), Rory J. Radding (Reg. No. 28749), Stephen J. Harbulak (Reg. No. 29166), Donald J. Goodell (Reg. No. 19766), James N. Palik (Reg. No. 25510), Thomas E. Friebel (Reg. No. 29258), Laura A. Coruzzi (Reg. No. 30742), Jennifer Gordon (Reg. No. 30753), Jon R. Stark (Reg. No. 30111), Allan A. Fanucci (Reg. No. 30256), Geraldine F. Baldwin (Reg. No. 31232), Victor N. Balancia (Reg. No. 31231), Samuel B. Abrams (Reg. No. 30605), Steven I. Wallach (Reg. No. 35402), Marcia H. Sundeen (Reg. No. 30893), Paul J. Zegger (Reg. No. 33821), Edmond R. Bannon (Reg. No. 32110), Bruce J. Barker (Reg. No. 33291), Adriane M. Antler (Reg. No. 32605), Ann L. Gisolfi (Reg. No. 31956), Mark A. Farley (Reg. No. 33170), and James G. Markey (Reg. No. 31636), all of Pennie & Edmonds LP, whose addresses are 1155 Avenue of the Americas, New York, New York 10036, 1667 K Street N.W., Washington, DC 20006 and 3300 Hillview Avenue, Palo Alto, CA 94304, and each of them, my attorneys, to prosecute this application, and to transact all business in the Patent and Trademark Office connected therewith.

PATENTED

FILING DATE

(1) CA1 - 209524.1

STATUS

PENDING

ABANDONED

SEN	D CORRESPONDEN	CE TO: PENNIE & EDMONDS 1155 AVENUE OF THE NEW YORK, N.Y. 1003	AMERICAS		TELEPHONE CALL & EDMONDS _{LLP} DO 2803	
	FULL NAME OF INVENTOR	LAST NAME MARTON	FIRST NAME MATTHEW	-	MIDDLE NAME	!
2 0 1	RESIDENCE & CITIZENSHIP	CITY SEATTLE	STATE OR FOREIGN COUNTRY WASHINGTON		COUNTRY OF CITIZENSHI USA	P
	POST OFFICE ADDRESS	STREET 2415 NW 91st	SEATTLE	,	STATE OR COUNTRY WASHINGTON	ZIP CODE 98117
	FULL NAME OF INVENTOR	LAST NAME STOUGHTON	FIRST NAME ROLAND		MIDDLE NAME	
2 0 2	RESIDENCE & CITIZENSHIP	SAN DIEGO	STATE OR FOREIGN COUNTRY CALIFORNIA		COUNTRY OF CITIZENSHI USA	P
	POST OFFICE ADDRESS	STREET 425 WEST SPRUCE STREET	SAN DIEGO		STATE OR COUNTRY CALIFORNIA	21P CODE 92103

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 201	SIGNATURE OF INVENTOR 202
to Matthew A Marton MATTHEW MAR	ON Ruland Storth ROLAND STOUGHTON
2 -2 3 -99	DATE 2-23-99

(2)

CA1 - 209524.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	☑ Application of: Matthew Marton, et al. ☐ Patent of:				
Serial No.: 09/222,582☐ Patent No.:		Group Art Unit: To Be Assigned			
≅ Filed: December 28, 1998☐ Issued:		Examiner: To Be Assigned			
For:	METHODS FOR DETERMINING THERAPEUTIC INDEX FROM GENE EXPRESSION PROFILES	Attorney Docket No.: 9301-026-999			
VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS [37 CFR 1.9(f) and 1.27(c)] - Small Business Concern					
	nt Commissioner for Patents agton, D.C. 20231				
Sir:					
I hereb	y declare that I am				
 □ the owner of the small business concern identified below: ☒ an official of the small business concern empowered to act in behalf of the concern identified below: Name of concern Rosetta Inpharmatics, Inc. 					
Address of concern 12040 115 th Avenue, N.E. Kirkland, Washington 98034					
I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the person employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.					
I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern and/or there is an obligation under contract or law by the inventor(s) to convey rights to the small business concern with regard to the invention, entitled METHODS FOR DETERMINING THERAPEUTIC INDEX FROM GENE EXPRESSION PROFILES by inventor Matthew Marton, et al. in					
	☐ the specification filed herewith ☐ application serial no. 09/222,582 ☐ patent no. issued	filed December 28, 1998			

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who could not

CA1 - 209533.1

qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

FULL NAME				
ADDRESS				
	SMALL BUSINESS CONCERN	□ NONPROFIT ORGANIZATION		
FULL NAME		→		
ADDRESS				
	SMALL BUSINESS CONCERN	□ NONPROFIT ORGANIZATION		
FULL NAME				
ADDRESS				
	SMALL BUSINESS CONCERN	□ NONPROFIT ORGANIZATION		
status resulting in loss of en paying, the earliest of the i	file, in this application or patent, nontitlement to small entity status pricessue fee or any maintenance fee due to longer appropriate. [37 CFR 1.26]	or to paying, or at the time of a seafter the date on which		
statements made on inform statements were made with are punishable by fine or in United States Code, and th	atements made herein of my own k- lation and belief are believed to be the knowledge that willful false st imprisonment, or both, under Section at such willful false statements may lating thereon, or any patent to which	true; and further that these atements and the like so made on 1001 of Title 18 of the y jeopardize the validity of the		
Send correspondence and Direct Telephone calls to:	PENNIE & EDMONDS LLP 1155 Avenue of the Americas New York, N.Y. 10036-2711 (212) 790-9090			
Name of person signing	John J. King, II			
Title of person other than owner Senior Vice President and Chief Operating Officer				
Address of person signing Rosetta Inpharmatics, Inc. 12040 115th Avenue, Kirkland, Washington 98034				
Signatura Of O Use	12040 115" Avenue, Kirkland,	Washington 98034 Date 2.23.95		
Signature Yww.	·	Date 2.23.77		

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)